Medication Training Via Ignite Based on Roy Model in Heart Failure: Medication Adherence and Symptom Management

Condition(s) studied

Investigational drug(s) / intervention(s)

Ignite-Based Medication Management Training: The intervention is a structured medication management training program based on the Roy Adaptation Model. It is delivered using an Ignite digital presentation format and sent to participants via WhatsApp. The content is developed using current evidence-based heart failure guidelines (AHA and ESC) and focuses on improving patients' adaptation to illness through four adaptive modes (physiological, self-concept, role function, and interdependence). Participants receive the training after discharge and are followed up at 4 and 12 weeks using standardized symptom and medication adherence scales.

Study summary

The goal of this clinical trial is to learn if a structured medication training program can help people with heart failure better manage their condition. The program is based on the Roy Adaptation Model and is designed to support how people adjust to their illness.

The main questions it aims to answer are:

Does the training program improve heart failure symptoms? Does the training program help participants take their medications as prescribed?

Researchers will compare a training program group to a control group receiving standard care to see if the program is effective.

Participants will:

Be randomly assigned to either a training program group or a control group Receive the training program through WhatsApp after hospital discharge or receive standard discharge education Be followed for 12 weeks Complete questionnaires at the start of the study, at 4 weeks, and at 12 weeks

Eligibility

Primary outcome measure(s)

• Heart Failure Symptom Status Scale — 20 minutes
  This scale is used to assess the symptom burden associated with heart failure. Total scores range from 0 to 84, with higher scores indicating poorer health status and lower scores indicating better health status.

Trial sites (1)

More Saglik Bilimleri Universitesi trials in Turkey

Other trials for the same condition